Recombinant Human TYMP/PD-ECGF, N-His

Description of Recombinant Human TYMP/PD-ECGF, N-His

Introduction

Recombinant Human TYMP (thymidine phosphorylase)/PD-ECGF (platelet-derived endothelial cell growth factor) is a multifunctional protein that has been extensively studied in the field of cancer research. It is a promising drug target due to its role in tumor growth, angiogenesis, and metastasis. In this article, we will discuss the structure, activity, and potential applications of this protein in cancer treatment.

Structure of Recombinant Human TYMP/PD-ECGF

Recombinant Human TYMP/PD-ECGF is a 48 kDa homodimeric protein consisting of two identical subunits, each with 415 amino acids. It belongs to the family of nucleoside phosphorylases and is highly conserved among different species. The crystal structure of this protein has been determined, revealing a trimeric complex with two active sites per monomer.

Activity of this protein

Recombinant Human TYMP/PD-ECGF has two distinct enzymatic activities: thymidine phosphorylase and angiogenic factor. Thymidine phosphorylase is responsible for the conversion of thymidine to thymine and 2-deoxy-D-ribose-1-phosphate, which are essential for DNA synthesis. On the other hand, the angiogenic factor activity promotes the growth of new blood vessels, a process known as angiogenesis. This activity is crucial for tumor growth and metastasis.

Role as a Drug Target

The dual activity of Recombinant Human TYMP/PD-ECGF makes it an attractive drug target for cancer treatment. Inhibition of its thymidine phosphorylase activity can lead to a decrease in the production of DNA building blocks, ultimately leading to cell death. This approach has been explored in various studies, and several TYMP inhibitors have shown promising results in inhibiting tumor growth.

Moreover, targeting the angiogenic factor activity of Recombinant Human TYMP/PD-ECGF can prevent the formation of new blood vessels, thereby inhibiting tumor growth and metastasis. This approach has been validated in preclinical studies, and several anti-angiogenic drugs targeting this protein are currently in clinical trials for various types of cancer.

Potential Applications in Cancer Treatment

Recombinant Human TYMP/PD-ECGF has shown potential as a therapeutic target for various types of cancer, including breast, lung, and colon cancer. It has also been implicated in the development of resistance to chemotherapy drugs, making it an attractive target for combination therapy. In addition, this protein has been found to be overexpressed in tumor tissues compared to normal tissues, making it a specific target for cancer treatment.

Conclusion

In conclusion, Recombinant Human TYMP/PD-ECGF is a multifunctional protein with dual enzymatic activities that make it a promising drug target for cancer treatment. Its structure and activities have been extensively studied, and it has shown potential in inhibiting tumor growth, angiogenesis, and metastasis. Further research and clinical trials are needed to fully explore the therapeutic potential of this protein in cancer treatment.